Abstract:BACKGROUND Liver fibrosis is a compensatory response during the tissue repair process in chronic liver injury, and finally leads to liver cirrhosis or even hepatocellular carcinoma. The pathogenesis of hepatic fibrosis is associated with the progressive accumulation of activated hepatic stellate cells (HSCs), which can transdifferentiate into myofibroblasts to produce an excess of the extracellular matrix (ECM). Myofibroblasts are the main source of the excessive ECM responsible for hepatic fibrosis. Therefore, activated hepatic stellate cells (aHSCs), the principal ECM producing cells in the injured liver, are a promising therapeutic target for the treatment of hepatic fibrosis. AIM To explore the effect of taurine on aHSC proliferation and the mechanisms involved. METHODS Human HSCs (LX-2) were randomly divided into five groups: Normal control group, platelet-derived growth factor-BB (PDGF-BB) (20 ng/mL) treated group, and low, medium, and high dosage of taurine (10 mmol/L, 50 mmol/L, and 100 mmol/L, respectively) with PDGF-BB (20 ng/mL) treated group. Cell Counting Kit-8 method was performed to evaluate the effect of taurine on the viability of aHSCs. Enzyme-linked immunosorbent assay was used to estimate the effect of taurine on the levels of reactive oxygen species (ROS), malondialdehyde, glutathione, and iron concentration. Transmission electron microscopy was applied to observe the effect of taurine on the autophagosomes and ferroptosis features in aHSCs. Quantitative real-time polymerase chain reaction and Western blot analysis were performed to detect the effect of taurine on the expression of α-SMA, Collagen I, Fibronectin 1, LC3B, ATG5, Beclin 1, PTGS2, SLC7A11, and p62. RESULTS Taurine promoted the death of aHSCs and reduced the deposition of the ECM. Treatment with taurine could alleviate autophagy in HSCs to inhibit their activation, by decreasing autophagosome formation, downregulating LC3B and Beclin 1 protein expression, and upregulating p62 protein expression. Meanwhile, treatment with taurine triggered ferroptosis and ferritinophagy to eliminate aHSCs characterized by iron overload, lipid ROS accumulation, glutathione depletion, and lipid peroxidation. Furthermore, bioinformatics analysis demonstrated that taurine had a direct targeting effect on nuclear receptor coactivator 4, exhibiting the best average binding affinity of -20.99 kcal/mol. CONCLUSION Taurine exerts therapeutic effects on liver fibrosis via mechanisms that involve inhibition of autophagy and trigger of ferroptosis and ferritinophagy in HSCs to eliminate aHSCs.

Taurocholic Acid Promotes Hepatic Stellate Cell Activation Via S1PR2/p38 MAPK/YAP Signaling under Cholestatic Conditions

Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling

Glycocholic Acid Aggravates Liver Fibrosis by Promoting the Up-Regulation of Connective Tissue Growth Factor in Hepatocytes.

The Role of Sphingosine 1‐phosphate Receptor 2 in Bile‐acid–induced Cholangiocyte Proliferation and Cholestasis‐induced Liver Injury in Mice

Lipopolysaccharide mediates hepatic stellate cell activation by regulating autophagy and retinoic acid signaling.

Taurine attenuates activation of hepatic stellate cells by inhibiting autophagy and inducing ferroptosis

SAA1/TLR2 axis directs chemotactic migration of hepatic stellate cells responding to injury

JCAD Deficiency Attenuates Activation of Hepatic Stellate Cells and Cholestatic Fibrosis

Taurocholate Induces Cyclooxygenase-2 Expression Via the Sphingosine 1-Phosphate Receptor 2 in A Human Cholangiocarcinoma Cell Line

Trichostatin A Inhibits the Activation of Hepatic Stellate Cells by Increasing C/EBP-α Acetylation in Vivo and in Vitro.

P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases

CAT1 Silencing Inhibits TGF-β1-induced Mouse Hepatic Stellate Cell Activation in Vitro and Hepatic Fibrosis in Vivo.

Mechanism of Taurocholic Acid in Promoting the Progression of Liver Cirrhosis

Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 - β-catenin cascade to promote liver tumorigenesis

Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes.

Reversal of cholestatic liver disease by the inhibition of sphingosine 1-phosphate receptor 2 signaling

Effects of all-trans retinioc acid on expressions of COL1α2,MMP-2,TIMP-1, and signaling pathway in TGF-β1-simulated rat hepatic stellate cells

Liver Sinusoidal Endothelial S1pr2 Regulates Experimental Liver Fibrosis Through YAP/TGF‐β Signaling Pathway

Treatment of Cholestatic Fibrosis by Altering Gene Expression of Cthrc1: Implications for Autoimmune and Non-Autoimmune Liver Disease

MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization

Total astragalus saponins attenuate primary sclerosing cholangitis in mice by upregulation of TGR5